Olema Oncology

Olema Oncology is a biopharmaceutical company that focuses on developing innovative targeted therapies for women's cancers. Their lead program, OP-1250, is a potential best-in-class complete estrogen receptor antagonist (CERAN) designed to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Recently, they initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. The company was founded in 2007 and is headquartered in the United States. Supported by a team of experienced and accomplished scientists and board members, leading healthcare investors, and innovative pharma companies, Olema is strategically positioned to make significant advancements in the field of cancer treatment. Their commitment to innovation and strong backing from healthcare investors is demonstrated through their latest $130.00M Post-IPO Equity investment at 13 September 2023. Olema's dedication to developing novel therapies for women's cancers, along with their successful fundraising efforts, positions them as a promising player in the biopharma, biotechnology, healthcare, and pharmaceutical industries. For more information, visit their website at www.olema.com. (Note: Olema does not conduct interviews via text message or messaging platforms and does not ask candidates to download anything as part of the interview process. They utilize third-party tools for job advertisements, urging candidates to verify the communication's authenticity.)